PTC
MLTX icon

Private Trust Company’s MoonLake Immunotherapeutics MLTX Stock Holding History

Private Trust Company’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-52
Closed -$373 – 2631
2025
Q3 		$373 Sell
52
-68
-57% -$3.54K ﹤0.01% 2488
2025
Q2 		$5.66K Sell
120
-73
-38% -$2.97K ﹤0.01% 2015
2025
Q1 		$7.54K Hold
193
– – ﹤0.01% 1900
2024
Q4 		$10.5K Buy
193
+34
+21% +$1.74K ﹤0.01% 1739
2024
Q3 		$8.02K Buy
159
+37
+30% +$1.73K ﹤0.01% 1804
2024
Q2 		$5.36K Hold
122
– – ﹤0.01% 1899
2024
Q1 		$6.13K Sell
122
-16
-12% -$868 ﹤0.01% 1834
2023
Q4 		$8.33K Buy
138
+41
+42% +$2.11K ﹤0.01% 1720
2023
Q3 		$5.53K Buy
97
+63
+185% +$3.48K ﹤0.01% 1827
2023
Q2 		$1.73K Buy
+34
New +$915 ﹤0.01% 2124

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Private Trust Company's MLTX Position: Q4 2025 in Review

Private Trust Company sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 52 shares — an estimated $373 sold.

Private Trust Company first reported a position in MLTX in Q2 2023 and held it in 10 quarters. The position peaked at $10.5K in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Private Trust Company reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Private Trust Company sold 52 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $373.
  • Private Trust Company first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 10 quarters.
  • Private Trust Company's MoonLake Immunotherapeutics position peaked at $10.5K in Q4 2024.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Private Trust Company's 13F filing for Q4 2025, filed 26 Jan 2026.